ArticleCureus2025
Bullous Systemic Lupus Erythematosus As the Initial Presentation of Systemic Lupus Erythematosus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous systemic lupus erythematosus (BSLE) is a rare, autoantibody-mediated subepidermal blistering disorder. It typically occurs in patients with established systemic lupus erythematosus (SLE). We report a 55-year-old Hispanic female with no prior SLE history who developed bullous lesions later identified as BSLE. Skin biopsy and direct immunofluorescence showed subepidermal blisters, and these findings, along with her clinical presentation, confirmed the diagnosis. Linear deposition of IgG, complement C3, and collagen VII antibodies was found, which is highly characteristic and supportive of BSLE. In this clinical context, these immunopathologic findings are considered diagnostic; however, confirmation can be further supported by a rapid response to dapsone therapy. Oral dapsone therapy resulted in complete resolution within weeks. No residual scarring or pigmentation remained. This case highlights the importance of considering BSLE even in patients without classical lupus features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.